Overcoming the Bottlenecks in Financing Young Biotech Companies

Berger, Sascha

Editore: GRIN Verlag, 2013
ISBN 10: 3638946940 / ISBN 13: 9783638946940
Usato / Quantità: 0
Copie del libro da altre librerie
Mostra tutte le  copie di questo libro

Libro

Purtroppo questa copia non è più disponibile. Di seguito ti proponiamo una lista di copie simili.

Descrizione:

Gently used. Expect delivery in 20 days. Codice inventario libreria

Su questo libro:

Riassunto: Diploma Thesis from the year 2007 in the subject Business economics - Investment and Finance, grade: 1,3, Technical University of Munich (KfW Stiftungslehrstuhl für Entrepreneurial Finance), 148 entries in the bibliography, language: English, abstract: In this book the question of how to overcome specific bottlenecks in financing young biotech companies was posed. The answer is manifold and includes the the usage of the multitude of financial options. Hence, first, the unique characteristics of the industry were described and specific financial bottlenecks were revealed. The eminence of a major bottleneck, typically in the seed-phase of a biotech venture, was taken as reason for further elaborations. I based these elaborations primarily upon an analysis of interviews. Several qualitative and predominantly personal interviews were conducted in the Munich biotech cluster, covering three decisive groups of respondents: biotech executives and founders, venture capital investors and external industry experts. The obtained extensive experiences were finally collected, clustered and compared. My key finding was that this bottleneck is mainly rooted in the fact that, when a young biotech firm leaves the academia, a big money provider (a Venture Capitalist or corporate partner) is often not yet willing to invest. A technological proof-of-concept is demanded by the latter, which is, however, not yet sufficiently provided by the former. Cluster structures might generally be helpful, but do not change this fundamental logic either. Based on this analysis, and taking into account the many other revealed points to improve, I came up with an exhaustive roadmap how to tackle the bottlenecks, covering all major endogenous and exogenous factors. This list of suggestions was supplemented with some basic thoughts on biotech finance strategies as also lastly a description of a comprehensive biotech finance cycle.

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Dati bibliografici

Titolo: Overcoming the Bottlenecks in Financing ...
Casa editrice: GRIN Verlag
Data di pubblicazione: 2013
Condizione libro: very good

I migliori risultati di ricerca su AbeBooks

1.

Berger, Sascha
Editore: GRIN Verlag (2008)
ISBN 10: 3638946940 ISBN 13: 9783638946940
Nuovi Brossura Quantità: 15
Print on Demand
Da
Valutazione libreria
[?]

Descrizione libro GRIN Verlag, 2008. Condizione libro: New. This item is printed on demand for shipment within 3 working days. Codice libro della libreria LP9783638946940

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 16,99
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 9,99
Da: Germania a: Italia
Destinazione, tempi e costi

2.

Berger, Sascha
Editore: GRIN Verlag (2016)
ISBN 10: 3638946940 ISBN 13: 9783638946940
Nuovi Paperback Quantità: 1
Print on Demand
Da
Ria Christie Collections
(Uxbridge, Regno Unito)
Valutazione libreria
[?]

Descrizione libro GRIN Verlag, 2016. Paperback. Condizione libro: New. PRINT ON DEMAND Book; New; Publication Year 2016; Not Signed; Fast Shipping from the UK. No. book. Codice libro della libreria ria9783638946940_lsuk

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 28,64
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 5,27
Da: Regno Unito a: Italia
Destinazione, tempi e costi

3.

Berger, Sascha
Editore: GRIN Verlag (2013)
ISBN 10: 3638946940 ISBN 13: 9783638946940
Nuovi Paperback Quantità: 1
Da
Irish Booksellers
(Rumford, ME, U.S.A.)
Valutazione libreria
[?]

Descrizione libro GRIN Verlag, 2013. Paperback. Condizione libro: New. book. Codice libro della libreria 3638946940

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 46,00
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 11,04
Da: U.S.A. a: Italia
Destinazione, tempi e costi

4.

Sascha Berger
Editore: GRIN Verlag, Germany (2013)
ISBN 10: 3638946940 ISBN 13: 9783638946940
Nuovi Paperback Prima edizione Quantità: > 20
Print on Demand
Da
The Book Depository EURO
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro GRIN Verlag, Germany, 2013. Paperback. Condizione libro: New. 1. Auflage.. 206 x 145 mm. Language: English . Brand New Book ***** Print on Demand *****.Diploma Thesis from the year 2007 in the subject Business economics - Investment and Finance, grade: 1,3, Technical University of Munich (KfW Stiftungslehrstuhl fur Entrepreneurial Finance), 148 entries in the bibliography, language: English, abstract: In this book the question of how to overcome specific bottlenecks in financing young biotech companies was posed. The answer is manifold and includes the the usage of the multitude of financial options. Hence, first, the unique characteristics of the industry were described and specific financial bottlenecks were revealed. The eminence of a major bottleneck, typically in the seed-phase of a biotech venture, was taken as reason for further elaborations. I based these elaborations primarily upon an analysis of interviews. Several qualitative and predominantly personal interviews were conducted in the Munich biotech cluster, covering three decisive groups of respondents: biotech executives and founders, venture capital investors and external industry experts. The obtained extensive experiences were finally collected, clustered and compared. My key finding was that this bottleneck is mainly rooted in the fact that, when a young biotech firm leaves the academia, a big money provider (a Venture Capitalist or corporate partner) is often not yet willing to invest. A technological proof-of-concept is demanded by the latter, which is, however, not yet sufficiently provided by the former. Cluster structures might generally be helpful, but do not change this fundamental logic either. Based on this analysis, and taking into account the many other revealed points to improve, I came up with an exhaustive roadmap how to tackle the bottlenecks, covering all major endogenous and exogenous factors. This list of suggestions was supplemented with some basic thoughts on biotech finance strategies as also lastly a description of a comprehensive biotech finance cycle. Codice libro della libreria AAV9783638946940

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 49,60
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: Italia
Destinazione, tempi e costi

5.

Sascha Berger
Editore: GRIN Verlag
ISBN 10: 3638946940 ISBN 13: 9783638946940
Nuovi Paperback Quantità: 20
Print on Demand
Da
BuySomeBooks
(Las Vegas, NV, U.S.A.)
Valutazione libreria
[?]

Descrizione libro GRIN Verlag. Paperback. Condizione libro: New. This item is printed on demand. Paperback. 84 pages. Diploma Thesis from the year 2007 in the subject Economics Business: Investment and Finance, grade: 1, 3, Technical University of Munich (KfW Stiftungslehrstuhl fr Entrepreneurial Finance), 148 entries in the bibliography, language: English, abstract: In this book the question of how to overcome specific bottlenecks in financing young biotech companies was posed. The answer is manifold and includes the the usage of the multitude of financial options. Hence, first, the unique characteristics of the industry were described and specific financial bottlenecks were revealed. The eminence of a major bottleneck, typically in the seed-phase of a biotech venture, was taken as reason for further elaborations. I based these elaborations primarily upon an analysis of interviews. Several qualitative and predominantly personal interviews were conducted in the Munich biotech cluster, covering three decisive groups of respondents: biotech executives and founders, venture capital investors and external industry experts. The obtained extensive experiences were finally collected, clustered and compared. My key finding was that this bottleneck is mainly rooted in the fact that, when a young biotech firm leaves the academia, a big money provider (a Venture Capitalist or corporate partner) is often not yet willing to invest. A technological proof-of-concept is demanded by the latter, which is, however, not yet sufficiently provided by the former. Cluster structures might generally be helpful, but do not change this fundamental logic either. Based on this analysis, and taking into account the many other revealed points to improve, I came up with an exhaustive roadmap how to tackle the bottlenecks, covering all major endogenous and exogenous factors. This list of suggestions was supplemented with some basic thoughts on biotech finance strategies as also lastly a description of a comprehensive biotech finance cycle. This item ships from La Vergne,TN. Paperback. Codice libro della libreria 9783638946940

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 60,44
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 11,91
Da: U.S.A. a: Italia
Destinazione, tempi e costi